© 2013

Pharmacotherapy of Pulmonary Hypertension

  • Marc Humbert
  • Oleg V. Evgenov
  • Johannes-Peter Stasch

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 218)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Pulmonary Hypertension: Conceptual Bases of the Disease

    1. Front Matter
      Pages 1-1
    2. Marc Humbert, David Montani, Oleg V. Evgenov, Gérald Simonneau
      Pages 3-29
    3. Bradley A. Maron, Joseph Loscalzo
      Pages 31-58
    4. Peter Dorfmüller
      Pages 59-75
    5. Christopher J. Rhodes, John Wharton, Martin R. Wilkins
      Pages 77-103
    6. John J. Ryan, Glenn Marsboom, Stephen L. Archer
      Pages 105-149
  3. Pulmonary Hypertension: Established Therapies

    1. Front Matter
      Pages 151-151
    2. Ioana R. Preston
      Pages 153-160
    3. Marie-Camille Chaumais, Elise Artaud Macari, Olivier Sitbon
      Pages 161-175
    4. Horst Olschewski
      Pages 177-198
    5. Martine Clozel, Alessandro Maresta, Marc Humbert
      Pages 199-227
    6. Barbara A. Cockrill, Aaron B. Waxman
      Pages 229-255
  4. Pulmonary Hypertension: Novel Pathways and Emerging Therapies

    1. Front Matter
      Pages 277-277
    2. Johannes-Peter Stasch, Oleg V. Evgenov
      Pages 279-313
    3. Yoshihiro Fukumoto, Hiroaki Shimokawa
      Pages 351-363
    4. Serge Adnot, Amal Houssaini, Shariq Abid, Elisabeth Marcos, Valérie Amsellem
      Pages 365-380
    5. Eva Berghausen, Henrik ten Freyhaus, Stephan Rosenkranz
      Pages 381-408

About this book


This volume focuses on current evidence-based pharmacological treatments of various forms of pulmonary hypertension and provides a comprehensive review of the latest developments in this area. The first part of the book covers the definition, classification, pathophysiology, pathology, biomarkers and animal models of the disease, thus laying the conceptual basis for what follows. The middle section provides an overview of the established therapies, such as calcium channel blockers, prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors and inhaled nitric oxide. The last section explores novel pathways and emerging therapeutic approaches including soluble guanylate cyclase stimulators, Rho-kinase inhibitors, inhibitors of serotonin receptors and transporters, peptide growth factors, vasoactive peptides, modulators of redox equilibrium and cyclic nucleotide homeostasis, as well as immunosuppressive and anti-proliferative agents. Particular attention is given to the clinical applications of these experimental therapies, that are on the horizon. The book thus spans the continuum from basic science to clinical applications.


Vasoactive substances WHO Group I-V lung vasculature pulmonary artery pulmonary hypertension (PH) pulmonary vein

Editors and affiliations

  • Marc Humbert
    • 1
  • Oleg V. Evgenov
    • 2
  • Johannes-Peter Stasch
    • 3
  1. 1.Faculte´ de Me´decineUniv Paris-SudLe Kremlin BicêtreFrance
  2. 2.Dep of Anasthesia and Critical CareHarvard Medical School Massachusetts General HospitalBostonUSA
  3. 3.Cardiovascular ResearchBayer Pharma AGWuppertalGermany

Bibliographic information